Business Description
Alzamend Neuro Inc
NAICS : 541714
SIC : 2833
ISIN : US02262M6057
Share Class Description:
ALZN: Ordinary SharesTotal Employee Number:
7Description
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.35 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 77.5 | |||||
3-Year EPS without NRI Growth Rate | 77.4 | |||||
3-Year FCF Growth Rate | 74 | |||||
3-Year Book Growth Rate | -83.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.36 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.79 | |||||
9-Day RSI | 62.67 | |||||
14-Day RSI | 60.06 | |||||
3-1 Month Momentum % | 11.11 | |||||
6-1 Month Momentum % | -44.95 | |||||
12-1 Month Momentum % | -59.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.31 | |||||
Quick Ratio | 1.31 | |||||
Cash Ratio | 0.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -275.3 | |||||
Shareholder Yield % | -15.71 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -264.2 | |||||
ROA % | -198.1 | |||||
ROIC % | -2365.62 | |||||
3-Year ROIIC % | 2597.02 | |||||
ROC (Joel Greenblatt) % | -2366.63 | |||||
ROCE % | -263.96 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.05 | |||||
Price-to-Tangible-Book | 7 | |||||
EV-to-EBIT | -0.57 | |||||
EV-to-Forward-EBIT | -1.58 | |||||
EV-to-EBITDA | -0.58 | |||||
EV-to-Forward-EBITDA | -0.47 | |||||
EV-to-FCF | -0.62 | |||||
| Price-to-Net-Current-Asset-Value | 12.09 | |||||
Earnings Yield (Greenblatt) % | -175.44 | |||||
FCF Yield % | -158.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALZN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alzamend Neuro Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.9 | ||
| Beta | 0.5074 | ||
| 3-Year Sharpe Ratio | -2.8 | ||
| 3-Year Sortino Ratio | -2.25 | ||
| Volatility % | 61.28 | ||
| 14-Day RSI | 60.06 | ||
| 14-Day ATR ($) | 0.10813 | ||
| 20-Day SMA ($) | 1.209 | ||
| 12-1 Month Momentum % | -59.46 | ||
| 52-Week Range ($) | 0.84 - 2.89 | ||
| Shares Outstanding (Mil) | 3.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alzamend Neuro Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alzamend Neuro Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-12-09 | In 134 days | ||
| First quarter earnings results for 2027 | 2026-09-10 | In 44 days | ||
| Annual report for 2026 | 2026-07-22 | 1.32 (+7.32%) | ||
| General meeting for 2026 | 2026-04-17 12:00 | 1.00 (+0.04%) | ||
| Third quarter earnings results for 2026 | 2026-03-11 | 2.14 (+2.39%) | ||
| Second quarter earnings results for 2026 | 2025-12-09 | 2.25 (-1.32%) | ||
| First quarter earnings results for 2026 | 2025-09-10 | 2.37 (+3.95%) | ||
| Annual report for 2025 | 2025-07-22 | 3.26 (-0.31%) | ||
| 0.111111:1 Stock Split | 2025-05-12 | 5.92 (+21.87%) | ||
| General meeting for 2025 | 2025-04-25 12:00 | 6.31 (+2.73%) |
Show
Entries
Alzamend Neuro Inc Frequently Asked Questions
What is Alzamend Neuro Inc(ALZN)'s stock price today?
The current price of ALZN is $1.33. The 52 week high of ALZN is $2.89 and 52 week low is $0.84.
When is next earnings date of Alzamend Neuro Inc(ALZN)?
The next earnings date of Alzamend Neuro Inc(ALZN) is 2026-09-10 Est..
Does Alzamend Neuro Inc(ALZN) pay dividends? If so, how much?
Alzamend Neuro Inc(ALZN) does not pay dividend.
Guru Commentaries on NAS:ALZN
No articles.
Press Release
Articles on Alzamend Neuro Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers